Compare OGI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGI | MOLN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Canada | Switzerland |
| Employees | 1137 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.0M | 151.9M |
| IPO Year | 2015 | 2021 |
| Metric | OGI | MOLN |
|---|---|---|
| Price | $1.07 | $4.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 528.2K | 3.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | $374.07 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $3.41 |
| 52 Week High | $2.24 | $5.36 |
| Indicator | OGI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 53.15 |
| Support Level | N/A | $4.04 |
| Resistance Level | $1.21 | $4.49 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 12.12 | 83.03 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.